Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022
   Pooled it
2. Safety and Tolerability of Contezolid Versus Linezolid for Short-Term Treatment of Rifampicin-Resistant Pulmonary Tuberculosis: A Randomized Controlled Study.Infection and drug resistance · 2025
   Article
3. Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective.PLOS global public health · 2023
   Article
4. Tools to Alleviate the Drug Resistance inMolecules (Basel, Switzerland) · 2022
   Review
5. A Novel Para-Amino Salicylic Acid Magnesium Layered Hydroxide Nanocomposite Anti-Tuberculosis Drug Delivery System with Enhanced in vitro Therapeutic and Anti-Inflammatory Properties.International journal of nanomedicine · 2021
   Article
6. Integration of drug safety monitoring in tuberculosis treatment programmes: country experiences.European respiratory review : an official journal of the European Respiratory Society · 2019
   Review
7. Barriers and facilitators to early access of bedaquiline and delamanid for MDR-TB: a mixed-methods study.Public health action · 2019
   Article
8. Recent evidence on delamanid use for rifampicin-resistant tuberculosis.Journal of thoracic disease · 2019
   Article
9. Transmission of drug-resistant tuberculosis in HIV-endemic settings.The Lancet. Infectious diseases · 2019
   Review
10. An update on multidrug-resistant tuberculosis .Clinical medicine (London, England) · 2019
    Article
11. Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging.Drug development research · 2019
    Review
12. Telemedicine in Resource-Limited Settings to Optimize Care for Multidrug-Resistant Tuberculosis.Frontiers in public health · 2019
    Article
13. Notes from the Field: Acquisition of Delamanid Under a Compassionate Use Program for Extensively Drug-Resistant Tuberculosis - United States, 2017.MMWR. Morbidity and mortality weekly report · 2018
    Article
14. Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa.The European respiratory journal · 2018
    Article
15. New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2018
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as